# Articles & insights to keep you updated on our latest developments

Stay up-to-date with our latest platform developments.

### Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers

Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …

[**Read more**](/content/blog/navigating-eylea-(aflibercept/index.html)-prior-authorization-policies-across-major-u-s-payers)

### Recent Posts

**Audit Readiness for Infusion & SP: Documentation That Survives Payer Reviews**  
[Jul 28, 2025](/content/blog/audit-readiness-for-infusion-sp-documentation-that-survives-payer-reviews/index.html)

**Units, Modifiers, and MUE Pitfalls: Coding Essentials for Infusion Services**  
[Jul 28, 2025](/content/blog/units-modifiers-and-mue-pitfalls-coding-essentials-for-infusion-services/index.html)

**Buy‑and‑Bill Denial Prevention: Top 10 Root Causes and How to Fix Them**  
[Jul 28, 2025](/content/blog/buy-and-bill-denial-prevention-top-10-root-causes-and-how-to-fix-them/index.html)

**Vial Optimization & JW Modifier: Cut Drug Waste and Denials**  
[Jul 28, 2025](/content/blog/vial-optimization-jw-modifier-cut-drug-waste-and-denials/index.html)

**NDC‑to‑HCPCS Crosswalk Guide: Avoid J‑Code Errors on Infusion Claims**  
[Jul 28, 2025](/content/blog/ndc-to-hcpcs-crosswalk-guide-avoid-j-code-errors-on-infusion-claims/index.html)

**Medicare Part B Drug-Pricing Reforms Coming in 2026—What Providers Should Do Now**  
[Jul 11, 2025](/content/blog/medicare-part-b-drug-pricing-reforms-coming-in-2026-what-providers-should-do-now/index.html)

**Navigating 340B, Site-Neutral & Prior-Auth Rules After the 2025 Executive Order**  
[Jul 11, 2025](/content/blog/navigating-340b-site-neutral-prior-auth-rules-after-the-2025-executive-order/index.html)

**Biosimilars in 2025: Adoption Strategies That Save Infusion Centers 20 % on Drug Spend**  
[Jul 11, 2025](/content/blog/biosimilars-in-2025-adoption-strategies-that-save-infusion-centers-20-on-drug-spend/index.html)

**Remicade (infliximab) Prior-Authorization Guide: Policies, Codes & Access Insights**  
[Jul 10, 2025](/content/blog/remicade-(infliximab/index.html)-prior-authorization-guide-policies-codes-access-insights)